The efficacy of naftopidil in treatment of female urethral syndrome / 医学研究生学报

ABSTRACT

Objective: To evaluate the efficacy and safety of Naftopidil on patients with female urethral syndrome (FUS). Methods: Self-controlled clinical trial was performed in patients with FUS. Thirty-eight patients were treated with naftopidil tablet 25mg/po/qn for 4 weeks after one-week washout period. The effects were evaluated mainly by female urethral syndrome score (FUSS) and quality of life (QOL). Results: FUSS began to decrease after 2 (week's) administration and decreased significantly after 4 weeks' treatment. It had statistically significant difference of FUSS and QOL after treatment compared with control (P